61.48 +0.35 (0.57%)
After hours: 5:51PM EDT
|Bid||52.52 x 1300|
|Ask||61.14 x 800|
|Day's Range||60.00 - 61.50|
|52 Week Range||41.85 - 73.99|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||12.59|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.07|
Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.
Henry Schein, Inc. announced that it will present at three virtual investor conferences in June.
With me on the call today are Stanley Bergman, chairman of the board and chief executive officer of Henry Schein; and Steven Paladino, executive vice president and chief financial officer. Before we begin, I would like to state that certain comments made during this call will include information that is forward looking.
Henry Schein Thrive Practice Recovery Program available to help dentists safely return to providing care.
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Contribution from Henry Schein's (HSIC) medical business in the form of point-of-care antibody rapid test is likely to have boosted Q1 performance amid the coronavirus pandemic.
Henry Schein, Inc. will release its first quarter 2020 financial results before the stock market opens on Tuesday, May 5, 2020.
Since the virus scare began, and during the economy’s swing from bull to bear, investment bank Goldman Sachs has kept its finger on the pulse of the stock market. Fortunately for investors, the bank predicts that the S&P 500 won’t register new lows, and has been advising clients to ‘buy the dip.’Silvia Ardagna, of the GS Private Wealth Management investment strategy group, noted, “Our own advice to clients is that right now is a good time to get back into markets and take advantage of the decline in equity markets to position for the rebound.”Ardagna and her team see a recession developing for 1H20, caused by the economic impact of coronavirus and the measures taken to combat the epidemic, but remain “positively impressed” by the response from policymakers. Predicting a V-shaped recovery, she believes that a strong recovery is likely in the second half of the year.We’ve looked into Goldman's recent calls, and using the TipRanks database, we’ve chosen two of the firm's recent stock picks, and one that demands more caution from investors. Let’s take a closer look.CSX Corporation (CSX)We’ll start in the transportation industry, where CSX, a holding company, operates through its subsidiaries. The company’s rail transport subsidiaries are located primarily in the eastern US (the company’s name is derived from the old Chesapeake and Ohio Railroad), while other services, including container shipping, barge transport, and contract logistics are provided worldwide.Heading into the coronavirus disruptions, CSX started out with a strong position. The company reported 99 cents EPS in the fourth quarter, beating the estimate by 2%, the $2.9 billion in quarterly revenue was also over the forecast. But what about the current coronavirus quarter?Covering this stock for Goldman Sachs, analyst Jordan Alliger writes, “While the upcoming quarters certainly bring elevated EPS risk … we believe CSX on a 12-month basis offers solid risk/reward… The combination of valuation support, operational strength, and liquidity, plus cyclical positioning for eventual recovery makes overweight exposure to rails desirable upon virus containment.”Alliger backs up his long-term optimism with a rating upgrade, bumping CSX shares from Neutral to Buy. His $75 price target suggests an upside potential of 25% for the coming year. (To watch Alliger’s track record, click here)Overall, CSX holds a Moderate Buy rating from the analyst consensus. This is a based on a 9-8 split among the recent reviews of Buys versus Holds. Shares are selling for $60 now, and the average price target of $69 implies 14.5% upside from current levels. (See CSX stock analysis on TipRanks.)Henry Schein, Inc. (HSIC)Next up, we move to the healthcare industry, a segment that is, in time, sure to see a positive bounce due to the coronavirus. As efforts expand to contain and control the spread of the COVID-19 disease, healthcare and its various support services will be in high demand.Henry Schein distributes healthcare products and services in over 30 countries. The company offers services for business, clinical, technology, and supply chain solutions, especially tailored to the medical and dental industries.Like CSX above, HSIC started 2020 – and faced the coronavirus epidemic – following strong Q4 results. Revenues came in at $2.67 billion, matching the forecast and up 8.1% year-over-year, and the EPS of 97 cents was up 8.9% yoy and beat the forecast by 6.6%. The company’s Medial and Technology/Value-added services led the revenue gains, growing 15% and 20% respectively. Even better, for the current climate, HSIC finished 2019 with $106.1 million in cash on hand, up nearly $50 million from year before.Goldman Sachs analyst Nathan Rich lays out the case for optimism here: “We think HSIC faces lower earnings risk than peers from the COVID n outbreak and its business may be quicker to recover... HSIC’s Medical segment should beneﬁt from the distribution of COVID tests, which could help to mitigate the impact of lower dental/physician ofﬁce trafﬁc.” In other words, Henry Schein’s leading position in the healthcare industry during a time of pandemic crisis, place it in a strong position for future growth.Rich’s Buy rating on the stock represents an upgrade from Neutral, and his $59 price target implies room for 13% growth in the coming 12 months. (To watch Rich’s track record, click here)Wall Street tends to agree with the analyst's confidence on the healthcare player, considering TipRanks analytics reveal HSIC as a Strong Buy. Out of 4 analysts tracked in the last 3 months, 3 are bullish on Henry Schein stock while 1 remains sidelined. With a return potential of nearly 25%, the stock's consensus target price stands at $65. (See Henry Schein stock analysis onTipRanks.)Xylem, Inc. (XYL)Not all stocks are so well positioned for gains, even if they inhabit essential industries. Xylem is a player in the water and wastewater niche, providing services that address the full water cycle, from collection to distribution to its return to the environment. Xylem’s products include pumps, valves, heat exchangers, dispensing equipment, and treatment and testing equipment.Water is essential to life, and reputable performers in the water industry can usually build a solid niche. Xylem finished 2019 with $5.25 billion in revenues, net income of $401 million, and a strong balance sheet including $1.7 billion on hand in liquid assets and available credit.But in a flashing warning sign for investors, Xylem on March 31 withdrew its 2020 guidance, citing the impact of COVID-19. The company has previously indicated a 1% to 2% revenue loss in Q1 when the virus first began to spread – but as it became an epidemic, and then spread worldwide, Xylem saw the impact on business and supply chains as more disruptive. Revising guidance would make sense in that environment – but Xylem simply withdrew its forecast without replacing it, leaving investors up in the air.Brian Lee, in his coverage of the stock for Goldman Sachs, sees a possible reason for the company’s guidance move – a reason that also prompts him to downgrade this stock from Neutral to Sell. He writes, “Based on our sensitivity analysis framework across our water coverage, we see greater downside risk to XYL’s fundamentals in light of the COVID-19 headwinds, largely given the company’s limited recurring revenue exposure… [this] leaves the company more exposed to the potential downturn in new demand…”Lee’s Sell rating is accompanied by a lower price target of $56, indicating his view that the stock will slip by 16% this year. (To watch Lee’s track record, click here)All in all, Xylem’s Hold rating from the analyst consensus is based on 11 recent reviews, including a single Buy, 8 Holds, and 2 Sells. Wall Street is not sanguine about this stock. Shares are trading at $66.68, while the $68.22 average price target suggests an upside potential of merely 2%. (See Xylem stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Henry Schein Medical, the U.S. medical business of Henry Schein, Inc., announced today the availability of VisualDx to assist health care professionals seeing patients virtually or in person amid the novel COVID-19 outbreak. The web-based, clinical decision support system is designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient care, all critically important for clinicians on the front lines of medicine.
Henry Schein, Inc. (Nasdaq: HSIC) announced today its latest virtual resource to help dental and medical practice owners navigate the COVID-19 pandemic. "Best Practices for Better Practices: A Henry Schein Wellness Symposium," will launch on Thursday, April 9 at 10:00 a.m. EST. To register, click here.
Henry Schein Inc. said it was withdrawing its financial guidance provided in February, citing the growing impact of the coronavirus pandemic on its business. The health care products and services company said it was temporarily cutting salaries of its senior executives, with Chief Executive Stanley Bergman agreeing to a 100% reduction in his base salary from April 6 through June 30. The chief financial officer and the other three most highly paid executives will have salaries reduced by 50%, while management at the director level through senior vice president will have salaries reduced from 10% to 25%. The company said other measures taken to preserve cahs include the suspension of its share repurchase program. The stock, whch gained 1.4% in premarket trading, has lost 31.1% over the past three months through Friday, while the S&P 500 has declined 23.3%.
But the note by Citigroup analysts does not explain where these millions of serological tests are going to come from, so some skepticism is in order.
Henry Schein named exclusive distributor of a second serology test and participates in White House COVID-19 Supply Chain Task Force.
UPS has provided more insight into its "unprecedented" collaboration with the federal government as it fights against the coronavirus epidemic
A planeload of desperately needed medical supplies arrived in New York from China on Sunday, the first in a series of flights over the next 30 days organized by the White House to help fight the coronavirus, a White House official said. A commercial carrier landed at John F. Kennedy airport carrying gloves, gowns and masks for distribution in New York, New Jersey and Connecticut, three hard-hit states battling to care for a crush of coronavirus patients. The airlift is a product of a team led by White House senior adviser Jared Kushner, which formed "Project Airbridge," a partnership between large U.S. healthcare distributors such as McKesson Corp, Cardinal, Owens & Minor, Medline and Henry Schein Inc, and the federal government.
Henry Schein, Inc. announced the availability of a point-of-care antibody rapid blood test, known as Standard Q COVID-19 IgM/IgG Rapid Test.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.